News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Medicine Recall – Marevan® (Warfarin) 3mg Tablets

Medicine Recall – Marevan® (Warfarin) 3mg Tablets (Blue)


Recall of Marevan® (warfarin) 3mg tablets (blue)
GlaxoSmithKline New Zealand (GSK), in consultation with Medsafe, is recalling all Marevan (warfarin) 3mg tablets (blue) dispensed to patients since 23 November 2009.
Marevan® is an anticoagulant treatment used widely in New Zealand to thin blood to help prevent blood clots. Marevan® 3mg tablets are blue in colour.
The recall is due to a manufacturing problem that could mean that a limited number of the Marevan® (warfarin) 3mg tablets (blue) may contain more medicine than the labelled amount.

If a patient has taken a Marevan ® (warfarin) 3mg tablet (blue) from the affected batch, it may place the patient at an increased risk of bruising and/or bleeding. Signs of increased anticoagulant activity include abnormal bleeding or bruising, vomiting with the appearance of coffee grounds or blood, blood in the urine or stool, or black tarry stools.
Patients who have received their Marevan® 3mg tablets (blue) after 23 November 2009 are advised to:

1. Not suddenly stop taking this treatment.

2. Seek advice and replacement tablets as soon as possible.

3. Return the Marevan® (warfarin) 3mg tablets (blue) to their pharmacy for free replacement, if required.

4. Contact the doctor or clinic that prescribed their medicine for advice on whether further testing or monitoring is required.

5. Contact their doctor immediately if any ill effects are noticed.


GSK is working with doctors and pharmacists to contact any patients who may be affected by this batch recall.
“Patient safety is our first concern and the results of our investigations to date give us confidence that this is an isolated incident. If patients have any concerns about their medication, they should discuss these with their pharmacist or their health practitioner,” said Geoff McDonald, General Manager at GSK New Zealand.
Marevan® (warfarin) is available in three different strengths – 1mg (brown), 3mg (blue) and 5mg (pink). This recall only affects the Marevan® (warfarin) 3mg tablets (blue) and does not affect any other batches or strengths, or any other GSK products.

GSK sincerely regrets any inconvenience and is confident that supply to customers will not be affected by this recall activity.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Francis Cook: Gallipoli: The Scale Of Our War – First Look

Te Papa today allowed media access to their new exhibition Gallipoli: The Scale of Our War . The exhibition was curated with help from Weta Workshop to deliver an immersive, realistic and even disorienting experience. More>>

ALSO:

Bats Theatre: Letters From The Front Brings ANZAC Letters Alive

Inspired by centenary commemorations, improv troupe Best on Tap is producing a show based on real-life letters sent to and from New Zealand soldiers in the First World War. More>>

ALSO:

Publishing: Unity Books On Plan To Close Te Papa Press

Unity Books is alarmed that Te Papa is proposing to suspend publishing by Te Papa Press for 4 or 5 years. Te Papa Press has proven time and time again that it has both award and bestseller capability and fulfils its kaupapa. More>>

ALSO:

Cinema: ‘The Desk’ Featuring Paul Henry To Have NZ Debut

The Documentary Edge Festival is thrilled to announce The Desk as a late entry to its 2015 Programme. The film, featuring local broadcaster Paul Henry, will have its international premiere on May 21 at 10pm at Q Theatre (book now at qtheatre.co.nz) with limited screenings also on offer in Wellington and Auckland. More>>

ALSO:

Art: Considering Feminisms In Aotearoa New Zealand: Two Projects

Feminism is something that has changed our lives. Recently, the activist Marilyn Waring reviewed the impact of feminism in Aotearoa New Zealand and reminded us that just 40 years ago banks wouldn’t lend women money without the guarantee of a man, ... More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news